Cochrane · systematic review · CD010961

Perampanel add‐on for drug‐resistant focal epilepsy

Bresnahan, R, Hill, RA, Wang, J · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library

EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 2 · 28.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Perampanel add‐on versus placebo for drug‐resistant focal epilepsy

Population: people (aged 12 years and over) with drug‐resistant focal epilepsy
7 questions
OutcomeEffectEvidenceStatus / GRADE
≥ 50% reduction in seizure frequency
Perampanel add‐on vs placebo
RR 1.67 [1.43, 1.95]7 studies · 2524 participantsHigh
Seizure freedom
Perampanel add‐on vs placebo
RR 2.5 [1.38, 4.54]5 studies · 2323 participantsLow
Downgraded: imprecision
Treatment withdrawal due to any reason
Perampanel add‐on vs placebo
RR 1.3 [1.03, 1.63]7 studies · 2524 participantsLow
Downgraded: imprecision, inconsistency
Treatment withdrawal due to adverse effects
Perampanel add‐on vs placebo
RR 2.36 [1.59, 3.51]7 studies · 2524 participantsLow
Downgraded: imprecision, inconsistency
Proportion of participants who experienced ≥ 1 adverse effect
Perampanel add‐on vs placebo
RR 1.17 [1.1, 1.24]7 studies · 2524 participantsHigh
Proportion of participants who experienced ataxia
Perampanel add‐on vs placebo
RR 14.322 studies · 1098 participantsLow
Downgraded: imprecision
Proportion of participants who experienced dizziness
Perampanel add‐on vs placebo
RR 2.877 studies · 2524 participantsLow
Downgraded: inconsistency